Évaluation de l'Impact du Compressed Sensing Sur le Signal QSM
NCT ID: NCT04907487
Last Updated: 2026-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
82 participants
OBSERVATIONAL
2021-12-15
2025-05-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
MRI of routine care includes at least the following sequences:
* 3D T1 TFE (2 minutes)
* T2 TSE (2 minutes)
* 3D FLAIR (3 minutes)
The sequences added by the research lasting 25 minutes are:
* SWI QSM 1.0iso 8 echoes (10 minutes)
* SWI QSM 1.0iso 8 echoes CS 6 (7 minutes)
* SWI QSM 1.0iso 8 echoes CS 9 (5 minutes)
* SWI QSM 1.0iso 8 echoes CS 12 (3 minutes)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of the Impact of Gadolinium Injection on the Measurement of the QSM Signal
NCT04906941
Comparison of the Performance of an Optimized 3D EPI SWI Sequence and a Non-EPI QSM SWI Sequence in Detecting the Central Vein Sign in Patients With Multiple Sclerosis
NCT04705870
MRI Exploration of Meningeal Inflammatory Disease
NCT04707170
Optimization of Sequences to Improve the Quality and Comfort of the Magnetic Resonance Imaging Examination
NCT05326581
OPTIMIZATION of ADVANCED MR SEQUENCES
NCT05618990
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
MRI of routine care includes at least the following sequences:
* 3D T1 TFE (2 minutes)
* T2 TSE (2 minutes)
* 3D FLAIR (3 minutes)
The sequences added by the research lasting 25 minutes are:
* SWI QSM 1.0iso 8 echoes (10 minutes)
* SWI QSM 1.0iso 8 echoes CS 6 (7 minutes)
* SWI QSM 1.0iso 8 echoes CS 9 (5 minutes)
* SWI QSM 1.0iso 8 echoes CS 12 (3 minutes)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SEP
With Multiple Sclerosis as defined by McDonald's revised clinical or radiological spatial and temporal dissemination criteria
MRI
MRI of routine care includes at least the following sequences:
* 3D T1 TFE (2 minutes)
* T2 TSE (2 minutes)
* 3D FLAIR (3 minutes)
The sequences added by the research lasting 25 minutes are:
* SWI QSM 1.0iso 8 echoes (10 minutes)
* SWI QSM 1.0iso 8 echoes CS 6 (7 minutes)
* SWI QSM 1.0iso 8 echoes CS 9 (5 minutes)
* SWI QSM 1.0iso 8 echoes CS 12 (3 minutes)
NO SEP
For patients with an indication to undergo a brain MRI and at low risk of inflammatory CNS disease
MRI
MRI of routine care includes at least the following sequences:
* 3D T1 TFE (2 minutes)
* T2 TSE (2 minutes)
* 3D FLAIR (3 minutes)
The sequences added by the research lasting 25 minutes are:
* SWI QSM 1.0iso 8 echoes (10 minutes)
* SWI QSM 1.0iso 8 echoes CS 6 (7 minutes)
* SWI QSM 1.0iso 8 echoes CS 9 (5 minutes)
* SWI QSM 1.0iso 8 echoes CS 12 (3 minutes)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI
MRI of routine care includes at least the following sequences:
* 3D T1 TFE (2 minutes)
* T2 TSE (2 minutes)
* 3D FLAIR (3 minutes)
The sequences added by the research lasting 25 minutes are:
* SWI QSM 1.0iso 8 echoes (10 minutes)
* SWI QSM 1.0iso 8 echoes CS 6 (7 minutes)
* SWI QSM 1.0iso 8 echoes CS 9 (5 minutes)
* SWI QSM 1.0iso 8 echoes CS 12 (3 minutes)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient over 18 years old
* Presenting MS defined according to McDonald's revised criteria for spatial and temporal clinical or radiological dissemination \[16\],
* Should benefit as part of the care of an MRI examination with or without injection of gadolinium
* Express consent to participate in the study
* Affiliate or beneficiary of a social security scheme
For patients with an indication to undergo a brain MRI and at low risk of inflammatory CNS disease:
* Patient over 18 years old
* Should benefit as part of the care of an MRI examination with or without injection of gadolinium
* Express consent to participate in the study
* Affiliate or beneficiary of a social security scheme
Exclusion Criteria
* Patient benefiting from a legal protection measure
* Pregnant or breastfeeding woman
For patients with an indication to undergo a brain MRI and at low risk of inflammatory CNS disease:
* Patient benefiting from a legal protection measure
* Pregnant or breastfeeding woman
* Patient with inflammatory and / or demyelinating pathology of the CNS
* Motion artefact not allowing interpretation of images
* Patient who did not perform one of the following sequences: 3D T1 TFE, 3D FLAIR (for MS patients), SWI QSM 1.0iso 8 echoes.
Secondarily excluded patients will be replaced.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Ophtalmologique Adolphe de Rothschild
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hhopital fondation adolphe de rothschild
Paris, Paris, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JSY_2021_13
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.